Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 7/20 | 0.40 |
| ▸ | RARB | P10826 | 7/20 | 0.40 |
| ▸ | RARG | P13631 | 7/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125602 | 1.00 | PGR (0.42) | PGRMAPTNPC1RAB9ARARA | |
| SCHEMBL5122765 | 0.90 | TDP2 (0.53) | PGRMAPTNPC1RAB9ARARA | |
| SCHEMBL5122770 | 0.90 | TDP2 (0.53) | PGRMAPTNPC1RAB9ARARA | |
| SCHEMBL5125612 | 0.83 | CHEK1 (0.47) | PGRRARBRARGRXRA | |
| SCHEMBL5114379 | 0.82 | PGR (0.48) | PGRMAPTNPC1RAB9ARARA | |
| SCHEMBL5113501 | 0.82 | PGR (0.48) | PGRNPC1RAB9ARARARARB | |
| SCHEMBL5114381 | 0.82 | PGR (0.48) | PGRMAPTNPC1RAB9ARARA | |
| SCHEMBL5113496 | 0.82 | PGR (0.48) | PGRNPC1RAB9ARARARARB | |
| SCHEMBL4426122 | 0.81 | PGR (0.62) | PGRMAPTNPC1RAB9ARARA | |
| SCHEMBL5113579 | 0.81 | PGR (0.49) | PGRRARARARBRARGRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414142-B2 | 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066637-A1 | 5-Aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators | CYP19A1, PGR, GNRHR | PGR 2/4885MAPT 4749/4885NPC1 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.